Ganciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients

Part of paid clinical trials in Houston, Texas.

Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Study ID
NCT05234723
Status
Recruiting
Apply to this trial

Conditions

  • Cytomegalovirus Infections

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The ReCySOHT study is a multicenter, retrospective, observational case-control study on the risk factors for developing a ganciclovir-resistant/refractory (GCV-RR) cytomegalovirus infection in patients receiving solid organ transplant (SOT) or hematopoietic stem cell transplant (HSCT). Aims of the study are to investigate the incidence of and risk factors for GCV-RR CMV infection in SOT recipients and HSCT patients in order to design further studies aimed at preventing and improving the patient management of GCV-RR CMV infections.

Key Dates

Start date
Jun 19, 2023
Status verified
Jun 2026
Primary completion
Feb 28, 2027
Completion
Feb 28, 2028

Study Design

Enrollment
100 participants (estimated)

Arms

  • Arm: Solid Organ Transplant and Hematopoietic Stem Cell Transplant patients
    Solid Organ Transplant (SOT) and Hematopoietic Stem Cell Transplant (HSCT) patients with Ganciclovir Resistant or Refractory Cytomegalovirus infection

Primary Outcome Measure

To define incidence of GCV-RR CMV-infection in SOT and HSCT patients [ Time Frame: Through study completion, an average of 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
MD Anderson Cancer CenterHoustonTexas77030-4009
Roy F. Chemaly
[email protected]

Find similar trials in Houston, TX

By research site
MD Anderson Cancer Center· Houston, TX

Related Studies